{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10"}]}],"title":"<= Day 12 post transplant"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Day 13 to 21 post transplant"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":">= Day 22 post transplant"}],"denomUnitsSelected":"Participants","denoms":[{"counts":[{"groupId":"OG000","value":"9"}],"units":"Participants"},{"counts":[{"groupId":"OG000","value":"10"}],"units":"transplantations"}],"description":"Polymorphonuclear cell (PMN) engraftment was defined as a PMN count ≥ 0.5\\*10\\^9/L for 3 consecutive days or ≥ 1\\*10\\^9/L for 1 day. Days to engraftment corresponded to the first day that the criteria were met after transplantation.","groups":[{"description":"Participants with MM who were eligible for autologous peripheral blood stem cell transplantation were given 240 µg/kg daily subcutaneous plerixafor for up to 4 days.","id":"OG000","title":"Participants With Multiple Myeloma (MM)"}],"paramType":"NUMBER","populationDescription":"Intent to treat population includes participants who received plerixafor and underwent transplantation. One participant had two transplants.","reportingStatus":"POSTED","timeFrame":"Approximately 2 months","title":"Number of Transplantations That Achieved Polymorphonuclear Leukocyte (PMN) Engraftment Grouped by Days to Engraftment","type":"SECONDARY","typeUnitsAnalyzed":"transplantations","unitOfMeasure":"transplantations"}